Recent advances in prophylactics and treatment of osteoporosis

Marian Szamatowicz1,2, Jacek Szamatowicz3
1Department of Medical Sciences Faculty of Health Sciences, Lomza State University of Applied Sciences Lomza, Poland  
2Department of Reproduction and Gynecological Endocrinology, Medical University of Bialystok, Bialystok, Poland  
3Department of Gynecology and Gynecological Oncology, Medical University of Bialystok, Bialystok, Poland

Abstract

Recently, a dramatic increase in the average life expectancy has been noted, regarded as the one of the greatest achievements of the last decades, but in consequence osteoporosis affects millions of people all over the world. Currently osteoporosis is defined as a skeletal disorder characterized by compromised bone strength which leads to an increased risk of fractures. The most commonly used tool to evaluate the 10-year risk of fractures is the fracture risk assessment tool validated in many independent cohorts. Osteoporosis itself has no symptoms, but fractures are common symptoms of osteoporosis which can result in disability and mortality. Hence, osteoporosis is called a silent epidemic as well as a silent killer. The best way to assess patients with osteoporosis is by using the most widely employed techniques – dual-energy X-ray absorptiometry or quantitative computed tomography. There are a lot of precisely documented risk factors of osteoporosis – e.g. cigarette smoking, alcohol use, getting little or no exercise, being small-framed or thin, a diet low in foods containing calcium and vitamin D – and their limitation or elimination is the best way for prophylactics of this dangerous disease. Some other risk factors such as age and sex of patients should not be omitted in the decision making process. In the literature there are numerous therapeutic proposals and different guidelines. In this review we present the recent advances in the prophylactics and treatment of osteoporosis.

Key words: osteoporosis, risk factors, prophylactics, treatment.

Introduction

Osteoporosis is a disease which is characterized by low bone mass resulting in increased risk of bone fractures that occur with low or minimal trauma, such as fractures occurring after falling from a standing position. Osteoporosis occurs most commonly in postmenopausal women [1]. Isolated low bone density and its influence on fractures in young women have no established clinical significance [2]. Bone fragility is an effect of decreased bone mineral density, that alters bone geometry and microarchitecture [3]. According to World Health Organization (WHO) recommendations, osteoporosis should be diagnosed upon results of bone mass density (BMD) measurements compared with the young adult reference population. An analysis of BMD during life span in women revealed that maximum bone density is achieved at the proximal femur in their 20s and at the spine and forearm around the age of 30 [4]. After that time bone loss starts in the perimenopausal period and is related to ovulatory disturbances. Women with a history of premenopausal fracture are in the group of higher risk of fracture during the postmenopausal period [5]. The case of association of bone loss with normal pregnancy remains controversial [6]. Nevertheless, lactation has more consistent and profound effects on bone density and is related to the duration of lactation and amenorrhea [7]. Circulating calcitonin, estrogen deficiency and parathyroid hormone-related protein are involved in bone mass loss in breastfeeding women [8]. Pregnancy and lactation-associated osteoporosis (PLO) is a rare condition of no known cause. Some studies suggest a strong genetic component of PLO [9]. Systematic reviews revealed an annual hip fracture rate from less than 100–600 per 100,000 and a vertebral fracture rate from 100–1400 per 100,000 depending on the region. The highest rates of hip fracture occurred in Scandinavia but the highest rates of vertebral fracture occurred in South Korea and in the United States [10]. There is a large number of risk factors responsible for the development of osteoporosis: advanced age, previous fracture, long-term glucocorticoid therapy, inflammatory bowel disease and celiac disease, premature ovarian failure and hypogonadotropic hypogonadism, low body weight, cigarette smoking, excess alcohol in-
take, long-term GnRH analog treatment due to cancer
disease, early oophorectomy due to cancer treatment,
race (higher risk in White than others) [11]. Regarding
risk factors for osteoporosis, other causes of decreased
bone mass should also be considered. Bone fractures
can be caused by osteomalacia or malignancy, or
decreased levels of estrogens during menopause. Physical
abuse should always be taken into account as a cause
of fracture. Also chronic kidney diseases should not be
omitted as a potential risk factor [12].

Osteoporosis screening

There can be established a probability of hip frac-
ture and major osteoporotic fractures within 10 years,
for untreated patients between the ages of 40 to 90,
based on the evaluation of risk factors indicated above
and femoral BMD. The so-called fracture risk assess-
ment tool (FRAX) was created at the University of Shef-
field in 2008. Since then, FRAX has been validated in
approximately 26 independent cohorts including data
from large observational studies. Although FRAX is
a useful tool for bone fracture prediction it should not
be used for monitoring results of the therapy [13]. Bone
mineral density in conjunction with established risk
factor assessment is then the best tool for osteoporosis
screening [14]. Nevertheless, low BMD is a bone fracture
prediction factor independently of the technique used
for the assessment [15]. Testing all women at 65 or
older and those with clinical risk factors is suggested.
Bone mass density is measured by dual-energy X-ray
absorptiometry (DXA) [16]. Many studies have demon-
strated that low DXA is a good diagnostic tool for oste-
oporotic fracture prediction and is used widely both for
screening and for osteoporosis treatment monitoring
[17]. Other techniques being practiced in osteoporotic
screening are quantitative computed tomography and
quantitative heel ultrasound, but they are not recom-
ended for osteoporotic screening because WHO cri-
tera for the diagnosis of osteoporosis are based on
BMD measured by DXA [18]. The effectiveness of oste-
oporosis screening has been evaluated and there was a
reduction in hip fractures compared to controls [19].
Results of trials revealed that quality of BMD measure-
ments together with risk factors analysis, appropriate
treatment and compliance of patients are responsible
for successful osteoporosis screening [20]. A meta-anal-
ysis of randomized controlled trials concluded that BMD
measurements together with subsequent osteoporosis
treatment reduces osteoporotic fractures but no differ-
ence in all-cause mortality has been observed [21]. Cost
effectiveness of osteoporosis screening is related to the
differences in health care costs and varies among the
countries [22]. There is a question of how often BMD
measurements should be repeated. It is obvious that
it would depend on the presence of osteoporosis risk fac-
tors and the results of initial measurements. In short, pa-
ients with low bone mass (T-score –2.00 to –2.49) and/or
with the presence of risk factors for bone loss ongoing
measurements of BMD should be advised every two
years. Patients with a T-score of –1.50 to –1.99 should
be tested in three to five years and finally patients with
a normal or slightly low T-score and with no risk factors
should undergo BMD measurements at a 10- to 15-year
interval [23]. It is important that osteoporosis screening
should be focused on identification of individuals at in-
creased risk of low trauma bone fracture and involve all
women at 65 years of age or older and younger wom-
en with risk factors present. The basic tool for BMD
measurements should be DXA. Patients during therapy
of osteoporosis or with clinical factors that can cause
accelerated bone loss should undergo BMD evalua-
tion more often. Three- to five-year intervals seem to
be effective enough [24]. The bone fracture usually is
the first clinical manifestation of osteoporosis and no
other symptoms are present. Even painful bones or
articles usually are not symptoms of the disease. Pain
is quite often a symptom of osteomalacia. The most
common symptoms of osteoporosis are bone fractures.
Vertebral fractures caused by osteoporosis are usually
asymptomatic and diagnosed incidentally on the
abdominal or chest radiograph. Other bone fractures
including hip fractures in older women are relatively
often caused by excessive bone mass loss [25]. Always
the evaluation for the risk of osteoporosis should start
with the history and a physical examination which could
exclude most of the conditions causing osteoporosis.
Fragility factors are very important when evaluating the
problem. Risk for another fracture in the next year is ap-
proximately 19% in women with vertebral fracture. Thus
this group of patients requires further evaluation and
treatment. In women with a T-score below –2.5 or with
risk factors biochemical tests should be recommended
(biochemistry profile including calcium, phosphorus, al-
bumin, total protein, liver enzymes, creatinine, vitamin
D and complete blood count ) [26]. These laboratory
tests may exclude other causes of osteoporosis such as
renal, liver disease, thyroid or parathyroid or adre-
nal diseases, hypoestrogenism, and celiac disease [27].
Quite often after the initial blood test patients may re-
quire further evaluation in order to exclude or include
renal function abnormalities, gastrointestinal disorders,
cancer or multiple myelomas or Cushing’s syndrome.
In contrast, markers of bone turnover have no estab-
lished role in the care of individual patients although
they may be helpful in understanding the mechanism
of action of therapeutic agents [28].

Pharmacological treatment of osteoporosis

As osteoporotic fractures cause significant morbidi-
ty and mortality this disease constitutes a major public
health problem and after precise osteoporotic screening the proper pharmacological treatment plays the crucial role. Everyone should remember that in clinical practice lifestyle measures should be adopted universally to reduce bone loss both in men and women. These measures include sufficient calcium and vitamin D supply, exercise such as weight-bearing physical activity, quitting smoking and limiting alcohol consumption. These recommendations have a documented beneficial effect on human bones [29–31]. Osteoporosis is typically associated with women, though this disease is an important and frequently overlooked problem in men. Although the risk of hip fracture is lower in men than in women, the risk of death is significantly higher in men. For men with osteoporosis pharmacological treatment is advised and bisphosphonates are the first-line agents for treating this disease, but for men with severe osteoporosis recombinant human parathyroid hormone preparations, such as teriparatide, are an acceptable option. For men with hypogonadism testosterone therapy is considered beneficial [32, 33].

The available therapies for osteoporosis are presently divided into two groups.

**Anti-resorptive agents**

**Bisphosphonates**

Bisphosphonate (alendronate, risedronate, ibandronate and zoledronic acid) preparations are used for both prevention and treatment of osteoporosis. The most frequently prescribed oral bisphosphonate is oral alendronic acid. It is important that this drug is taken correctly. The recommended way of treatment is as follows: in the morning with a glass of water, 45 min before food and remaining upright for about 30–60 min after the dose. This method of treatment allows one to avoid upper gastrointestinal side effects. However, there are patients who are unable to tolerate oral bisphosphonates (malabsorption or dysphagia); then intravenous bisphosphonate-zoledronic acid is a potential alternative. This drug has generally been used annually [30–32, 34].

**Denosumab**

Denosumab (PROLIA) is a human monoclonal antibody (IgG2), genetically engineered in hamster ovary cells. This antibody has high affinity and specificity for the human receptor activator RANKL, blocking its receptor RANK and in consequence inhibiting osteoclast formation, function and survival, thereby finally decreasing bone resorption. Denosumab is not recommended as initial therapy for most patients with osteoporosis but with exceptions at high risk for fractures. It is advised to administer the drug as a subcutaneous injection once every six months. The results from many clinical trials have shown that the treatment with denosumab leads to increased BMD and finally to reduction in risk of many fractures. In cases when denosumab is discontinued an alternative therapy with bisphosphonates is a good option [30, 35].

**Selective estrogen receptor modulators**

Selective estrogen receptor modulators (raloxifene, tamoxifen) are used primarily for the prevention and management of breast cancer. At the same time these compounds show an antiresorptive estrogenic effect on the skeleton. Selective estrogen receptor modulators advised in osteoporosis are not without side effects such as thromboembolic events and possibly hot flashes. Selective estrogen receptor modulators are usually chosen for osteoporosis when there is an independent need for breast cancer prophylaxis [30, 36].

**Estrogen/progestin therapy**

In postmenopausal women estrogens, even with progestins, have a positive effect on BMD but the time to observe favorable action of estrogens is rather long and this therapy should be advised with great caution due to serious side effects such as increased risk of breast cancer, stroke and venous thromboembolism. The main indication for estrogens in postmenopausal women should the occurrence of persistent hot flashes [30, 37].

**Anabolic agents**

**Parathyroid hormone/parathyroid hormone-related protein analog**

Very truly anabolic, bone-forming agents are teriparatide and abaloparatide – recombinant human parathyroid hormone peptide for subcutaneous injection. The possible candidates for anabolic agents are men and postmenopausal women but with severe osteoporosis or those who for various reasons are unable to tolerate bisphosphonates. In contrast to anti-resorptive agents, the above mentioned analogs of parathyroid hormone stimulate bone formation and activate bone remodeling [38–40].

**Romosozumab**

The humanized romosozumab (EVENITY), which binds sclerostin with high affinity and in consequence leads to an increase in bone density, was approved in 2019 by the US Food and Drug Administration for the United States and later on by the European Medicines Agency for Europe. This drug is intended for women with a history of osteoporotic fractures or multiple risk factors for fracture and also for those who have failed or are intolerant to other osteoporosis therapies. Everyone should remember that this new drug is not without some risk for heart attack, stroke or cardiovascular death [41]. It is very important to select patients for
this therapy carefully. Nevertheless, the safety and ef-
ficacy of romosozumab were clearly demonstrated first in
two clinical trials involving a total of 11,000 women
with postmenopausal osteoporosis [42, 43] and later on
confirmed by others [45, 46]. The recommended dose
of romosozumab is 210 mg by subcutaneous injection,
in two different places, monthly, during one year. Such
treatment significantly reduces vertebral and clinical
fractures by comparison with placebo and bisphospho-
nate [44–46].

Conclusions

In many countries a lot of different drugs and
preparations are used in the treatment of osteoporosis.
The experts of UpToDate, analyzing different publica-
tions, which show many conflicting results, present
the statement that drugs listed above should be advised
in the treatment of osteoporosis and other therapies
should not be recommended [30].

Disclosure

The authors report no conflict of interest.

References

1. Kanis JA, Melton LJ, Cristiansen C, Johnson CC, Khaltaev N. The diagnosis
of osteoporosis. J Bone Miner Res 1994; 9: 1137.
2. Ferrari S, Bianchi ML, Eisman JA, et al. Osteoporosis in young adults:
pathophysiology, diagnosis and management. Osteoporosis Int 2012;
23: 2735.
3. Siris ES, Adler R, Bilezikian J, et al. The clinical diagnosis of osteoporosis:
a position statement from the National Bone Health Alliance Working
Group. Osteoporosis Int 2014; 25: 1439-1443.
4. Sowers MR, Zheng H, Jannausch ML, et al. Amount of bone loss in rela-
tions to time around the final menstrual period and follicle-stimulating
hormone staging of the trans-menopause. J Clin Endocrinol Metab
2010; 95: 2155-2162.
5. Hosmer WD, Genant HK, Browner WS. Fractures before menopause: a red flag for physicians. Osteoporosis Int 2002; 13: 337.
6. Kyvernitakis I, Reuter TC, Hellmeyer L, Hars O, Hadji P. Subsequent
fracture risk of women with pregnancy and lactation-associated osteo-
porosis after a median of 6-years of follow-up. Osteoporosis Int 2018;
29: 139.
7. Lacoche M, Talibart M, Cermier C, Roux C, Guggenbuhl P, Degreve Y. Preg-
ancy-related fractures: a retrospective study of a French cohort of 52
patients and review of the literature. Osteoporosis Int 2017; 28: 3135.
8. Sowers MR, Hollis BW, Shapiro B, et al. Elevated parathyroid hormone-
related peptide associated with lactation and bone density loss. JAMA
1996; 276: 549.
9. Gehlen M, Lazaressu AD, Hinz C, et al. Long-term outcome patients with
pregnancy and lactation-associated osteoporosis (PLO) with a particular
focus on quality of life. Clin Reumatol 2019; 38: 3575.
10. Ballane G, Cauley JA, Luckey MM, El-Hajj Fuleihan G. Worldwide preva-
ience and incidence of osteoporotic vertebral fractures. Osteoporosis Int
2017; 28: 1531.
11. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip frac-
ture in white women. Study of Osteoporotic Fractures Research Group.
N Engl J Med 1995; 332: 767.
12. Johnell O, Kanis JA, Black DM, et al. Associations between baseline risk
factors and vertebral fracture risk in the Multiple Outcomes of Ralox-
ifene Evaluation (MORE) Study. J Bone Miner Res 2004; 19: 764.
13. Cadarette SM, Jaglal SB, Kreiger M, McIsaac WJ, Darlington GA, Tu JV.
Development and validation of the osteoporosis risk assessment instru-
ment to facilitate selection of women for bone densitometry. CMAJ
2000; 162: 1289.
14. Raisz LG. Clinical practice. Screening for osteoporosis. N Engl J Med
2005; 353: 164.
15. Kanis JA, Johnell O. Requirements for DXA for the management of osteo-
porosis in Europe. Osteoporosis Int 2005; 16: 229.
16. Wisvanathan M, Reddy S, Berkman N, et al. Screening to prevent os-
teoporotic fractures: evidence report and systematic review for the US
preventive service task force. JAMA 2018; 319: 2532.
17. Leslie WD, Tsang IF, Caetano PA, Liu LM. Manitoba Bone Density Pro-
gram. Effectiveness of bone density measurement for predicting osteo-
porotic fractures in clinical practice. J Clin Endocrinol Metab 2007; 92: 77.
18. Assessment of fracture risk and its application to screening for post-
menopausal osteoporosis. Report of a WHO Study Group. World Health
Organ Tech Rep Ser 1994; 843: 1-129.
19. Stone KL, Seeley DG, Lui LY, et al. Osteoporotic Fractures Research
Group. BMD at multiple sites and risk of fracture of multiple types: long-
term results from the Study of Osteoporotic Fractures. J Bone Miner Res
2003; 18: 1947.
20. Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and
other fractures. J Bone Miner Res 2005; 20: 1185.
21. Kanis JA, Gluer CC. Un update on the diagnosis and assessment of os-
teoporosis within densitometry. Committee of Scientific Advisors, Inter-
national Osteoporosis Foundation. Osteoporosis Int 2000; 11: 192.
22. Cummings SR, Cosman F, Lewiecki EM, et al. Goal-directed treatment for
osteoporosis: a progress report from the ASBMR-NOF Working Group on
goal-directed treatment for osteoporosis. J Bone Miner Res 2017; 32: 3.
23. Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous facture
and subsequent fracture risk. Bone 2004; 35: 375.
24. Papaloannou A, Moris S, Cheung AM, et al. Scientific Advisory Council
of Osteoporosis Canada. 2010 clinical practice guidelines for the diag-
nosis and management of osteoporosis Canada: summary. CMAJ 2010;
182: 1864.
25. Svedbom A, Hernlund E, Ivergard M, et al. EU Review Panel of IOF. O-
teoporosis in the European Union: a compendium of country – specific
reports. Arch Osteoporos 2013; 8: 137.
26. Tannenbaum C, Clark J, Schwartzman K, et al. Yield of laboratory testing
to identify secondary contributors to osteoporosis in otherwise healthy
women. J Clin Endocrinol Metab 2002; 87: 4431.
27. Hucdec SM, Camacho PM. Secondary causes of osteoporosis. Endocr
Pract 2013; 19: 120-128.
28. Hinga TT, Compston JE. Biochemical markers of bone turnover-uses and
limitations. Ann Clin Biochem 2014; 51: 189-202.
29. Loo JJ, Curtis EM, Cooper C, Harvey NC. State of the art. in osteoporosis
risk assessment and treatment. Endocrinol Invest 2019; 42: 1149-1164.
30. Rosen HN, Drezerz MR. Overview of the management of osteoporosis in
postmenopausal women. UpToDate (lastly accessed: Jul 19, 2022).
31. Reid IR. Effects of vitamin D supplements on bone density. J Endocrinol
Investig 2015; 38: 91-94.
32. Rao SS, Budhwar N, Ashfaque A. Osteoporosis in men. UpToDate
2010; 82: 503-508.
33. Poutousis M, Kenanidis E, Anagnostis P, Tsiridis E. Choosing appropriate
treatment strategy for ovarian cancer using oophorectomy. Expert Opinion
Pharmacother 2020; 21, 993-995.
34. Harvey NC, McClosky E, Kanis JA, Compston J, Cooper C. Biphospho-
nates in osteoporosis: NICE and easy? Lancet 2017; 390: 2243-2244.
35. Cummings SR, San Martin J, McClung MR, et al. Denosumab for preven-
tion of fractures in postmenopausal women with osteoporosis. N Engl
J Med 2009; 361: 756-765.
36. Lufkin EG, Whitaker MD, Nickelsen T, et al. Treatment of established
osteoporosis with raloxifene: a randomized trial. J Bone Miner Res
2009; 24: 1864.
37. Levin VA, Jiang X, Kagan R. Estrogen therapy for osteoporosis in the
modern era. Osteoporos Int 2018; 29: 1049-1055.
38. Eastell R, Walsh JS. Anabolic treatment for osteoporosis. teriparatide.
Clin Cases Miner Bone Metab 2017; 14: 173-178.
39. Langdahl B. Treatment of postmenopausal osteoporosis with bone-
forming and antiresorptive treatment: combined and sequential ap-
proaches. Bone 2020; 139: 115516.
40. Brent MB. Abaloparatide: a review of preclinical and clinical studies. Eur J Pharmacol 2021; 909: 174409.
41. Langdahl BL, Hofbauer LC, Forfar JC. Cardiovascular safety and sclerostin inhibition. J Clin Endocrinol Metab 2021; 106: 1845-1843.
42. Cosman F, Crittenden DB, Adachi JD, et al. Remosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 2016; 375: 1532-1543.
43. Saag KG, Petersen L, Brandi ML, et al. Remosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 2017; 377: 1417-1427.
44. Shoback D, Rosen C, Black DM, Cheung AM, Murad MH, Eastell R. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society Guideline Update. J Clin Endocrinol Metab 2020; 105: dgaa048.
45. Prather C, Adams E, Zentgraf W. Remosozumab: a first-in-class sclerostin inhibitor for osteoporosis. Am J Health Syst Pharm 2020; 77: 1949-1956.
46. Nealy KL, Harris KB. Remosozumab: a novel injectable sclerostin inhibitor with anabolic and antiresorptive effects for osteoporosis. Ann Pharmacother 2021; 55: 677-686.